In a recent multicenter retrospective study conducted by the Cell Therapy Consortium, clinicians assessed the real-world application of lisocabtagene maraleucel (liso-cel), an autologous CD19-directed CAR T-cell therapy approved for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The study, presented at the 65th ASH Annual Meeting and Exposition, aimed to provide insights into the safety and efficacy of liso-cel in standard clinical practice, extending beyond the controlled environment of clinical trials (Abstract 617).
December 11, 2023
Read moreData from a recent analysis that examined the impact of the differences between the two new classifications on real-world diagnosis of non-Hodgkin lymphoma (NHL) were presented during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9-12 in San Diego (Abstract 3708).
December 11, 2023
Read moreMAESTRO-Pool, a means of detecting circulating tumor DNA (ctDNA), could be sensitive and selective enough to help guide treatment decisions.
Dana-Farber Cancer Institute investigators, in collaboration with researchers from the Broad Institute, demonstrated in a retrospective clinical study that a novel test for ctDNA was more sensitive and more specific than existing tools for detecting relapse in patients with DLBCL after autologous stem cell transplantation.
December 11, 2023
Read moreIn the dynamically evolving landscape of large B-cell lymphomas (LBCLs), the classification and treatment paradigms have undergone significant transformations. Notably, the introduction of CD19-targeted CAR T-cell therapy (CAR-T) has marked a pivotal shift in the treatment approach.
December 10, 2023
Read morePatients with relapsed or refractory (R/R) aggressive large B-cell lymphoma (LBCL) who have already undergone first-line treatment often face a challenging prognosis. In recent years, numerous novel therapies have been approved for the treatment of R/R LBCL. However, conventional chemo-immunotherapy (CIT) regimens continue to be commonly used.
December 10, 2023
Read moreData from a Phase Ib/II study demonstrated the feasibility and curative potential of a multi-targeted therapy approach among patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to a recent oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9-12 in San Diego (Abstract 434).
December 10, 2023
Read morePreclinical data was presented at the 65th ASH Annual Meeting & Exposition in San Diego, by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine in New York City.
December 9, 2023
Read moreIn an innovative endeavor aimed at surmounting the hurdles of conducting clinical trials for untreated diffuse large B-cell lymphoma (DLBCL) among the elderly, a team of French researchers led by Benoît Tessoulin, MD/PhD, has unveiled a promising strategy involving synthetic control arms (SCA) generated from a blend of historical clinical trial data and real-world evidence.
December 9, 2023
Read moreFindings from a recent analysis suggest that older patients (ages 70-79) with diffuse large B-cell lymphoma (DLBCL) should undergo standard dose R-CHOP when feasible. Additionally, the data presented during the 65th American Society of Hematology (ASH) Annual Meeting, held December 9-12 in San Diego, showed that the primary determinant of outcomes among patients 80 years or older was not treatment intensity (Abstract 68).
December 9, 2023
Read more